This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Visterra, Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Kenneth Douglas Johnson: Innovator in Antibody Molecule-Drug Conjugates
Introduction
Kenneth Douglas Johnson is a notable inventor based in Marshfield, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody molecule-drug conjugates. His work focuses on innovative solutions for treating bacterial infections and related disorders.
Latest Patents
Kenneth holds a patent for "Antibody molecule-drug conjugates and uses thereof." This patent describes antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS). These conjugates can be utilized to treat, prevent, and diagnose bacterial infections, showcasing their potential in medical applications.
Career Highlights
Kenneth is currently associated with Visterra, Inc., where he continues to advance his research and development efforts. His expertise in antibody technology has positioned him as a key player in the biotechnology sector.
Collaborations
Some of Kenneth's notable coworkers include Karthik Viswanathan and Obadiah Joseph Plante. Their collaborative efforts contribute to the innovative environment at Visterra, Inc.
Conclusion
Kenneth Douglas Johnson's work in antibody molecule-drug conjugates represents a significant advancement in the treatment of bacterial infections. His contributions to biotechnology continue to impact the field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile